Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
CNS Drugs 25(6):503-9 (2011) PMID 21649450
Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine.
DOI: 10.2165/11590450-000000000-00000
Version: za2963e q8zac q8zb3 q8zc4 q8zdc q8zec q8zf9 q8zg0